COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study
COVID-19 and liver injury in patients with or without underlying liver disease: A multi-centre retrospective-prospective observational study.
All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 & prospective data from approval till 30/6/2020), will be included
Studieoversikt
Status
Forhold
Detaljert beskrivelse
COVID-19 and liver injury in patients with or without underlying liver disease: A multi-centre retrospective-prospective observational study.
All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 & prospective data from approval till 30/6/2020), will be included Primary objectives
- To study the prevalence of liver live injury & factors associated with among patients in-fected with SARS-CoV-2.
- To study the prevalence of new liver injury and factors associated with it, among patient with underlying liver disease who develops COVD-19.
Secondary objectives
- To correlate the presence and degree of liver dysfunction with the clinical outcomes in these patients.
- To define the incidence of development of acute liver failure among these patients
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
Dlelhi
-
New Delhi, Dlelhi, India, 110017
- Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 & prospective data from approval till 30/6/2020), will be included.
-
Exclusion Criteria:
- Patients less that 18 years old with COVID-19
- Pregnant ladies with COVD-19
- Unwilling to give consent for inclusion
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Annen
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
COVID-19 Positive Case
Tidsramme: 4-8 weeks
|
To study the prevalence of liver live injury & factors associated with among patients in-fected with SARS-CoV-2.
|
4-8 weeks
|
|
COVID-19 Positive Case
Tidsramme: 4-8 weeks
|
To study the prevalence of new liver injury and factors associated with it, among patient with underlying liver disease who develops COVID-19.
|
4-8 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
COVID-19 Positive Case
Tidsramme: 4-8 weeks
|
To correlate the presence and degree of liver dysfunction with the clinical outcomes in these patients.
|
4-8 weeks
|
|
COVID-19 Positive Case
Tidsramme: 4-8 weeks
|
To define the incidence of development of acute liver failure among these patients
|
4-8 weeks
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Kaushal Madan, DM, max healthcare
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- COVID 19/LI/2020
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .